进行HLA-B*5701检测以预测阿巴卡韦超敏反应。
HLA-B*5701 testing to predict abacavir hypersensitivity.
作者信息
Ma Joseph D, Lee Kelly C, Kuo Grace M
机构信息
University of California, San Diego, Skaggs School of Pharmacy & Pharmaceutical Sciences and University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences.
出版信息
PLoS Curr. 2010 Dec 7;2:RRN1203. doi: 10.1371/currents.RRN1203.
Abstract
Abacavir is a nucleoside reverse transcriptase inhibitor used for combination antiretroviral therapy for treating human immunodeficiency virus (HIV) infection. An adverse effect from abacavir is a treatment-limiting hypersensitivity reaction, which can be severe and potentially life-threatening. Abacavir-induced hypersensitivity reaction has been associated with the presence of the major histocompatibility complex class I allele HLA-B5701. A screening test for the HLA-B5701 allele can assist clinicians to identify patients who are at risk of developing a hypersensitivity reaction to abacavir.
摘要
阿巴卡韦是一种核苷类逆转录酶抑制剂，用于联合抗逆转录病毒疗法治疗人类免疫缺陷病毒（HIV）感染。阿巴卡韦的一种不良反应是限制治疗的超敏反应，这种反应可能很严重，甚至有潜在的生命危险。阿巴卡韦诱导的超敏反应与主要组织相容性复合体I类等位基因HLA - B5701的存在有关。对HLA - B5701等位基因进行筛查试验可帮助临床医生识别有发生阿巴卡韦超敏反应风险的患者。
相似文献
1
HLA-B*5701 testing to predict abacavir hypersensitivity.进行HLA-B*5701检测以预测阿巴卡韦超敏反应。
PLoS Curr. 2010 Dec 7;2:RRN1203. doi: 10.1371/currents.RRN1203.
3
HLA-B*5701 screening for hypersensitivity to abacavir.进行HLA-B*5701筛查以检测对阿巴卡韦的超敏反应。
N Engl J Med. 2008 Feb 7;358(6):568-79. doi: 10.1056/NEJMoa0706135.
4
Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.HLA B*5701基因分型在预防阿巴卡韦超敏反应中的成本效益分析。
Pharmacogenetics. 2004 Jun;14(6):335-42. doi: 10.1097/00008571-200406000-00002.
5
A Prospective Screening of HLA-B*57.01 Allelic Variant for Preventing the Hypersensivity Reaction to Abacavir: Experience from the Laboratory of Molecular Biology of the Infectious Diseases Division at the University Hospital of Salerno.前瞻性筛查HLA - B*57.01等位基因变异以预防对阿巴卡韦的超敏反应：来自萨勒诺大学医院传染病科分子生物学实验室的经验
Transl Med UniSa. 2014 Dec 19;11:55-8. eCollection 2015 Jan-Apr.
6
A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.一种基于HIV逆转录酶序列变异来降低与B*5701相关的阿巴卡韦超敏反应的简单筛查方法。
Clin Infect Dis. 2007 Jun 1;44(11):1503-8. doi: 10.1086/517499. Epub 2007 Apr 18.
7
Abacavir adverse reactions related with HLA-B*57: 01 haplotype in a large cohort of patients infected with HIV.在一大群感染艾滋病毒的患者中，阿巴卡韦不良反应与HLA - B*57:01单倍型的相关性。
Pharmacogenet Genomics. 2020 Oct;30(8):167-174. doi: 10.1097/FPC.0000000000000409.
8
9
Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.HLA-B*5701、HLA-DR7和HLA-DQ3的存在与对HIV-1逆转录酶抑制剂阿巴卡韦的超敏反应之间的关联。
Lancet. 2002 Mar 2;359(9308):727-32. doi: 10.1016/s0140-6736(02)07873-x.
10
High Frequency of Human Leukocyte Antigen-B*57:01 Allele Carriers among HIV-Infected Patients in Serbia.在塞尔维亚感染 HIV 的患者中人类白细胞抗原-B*57:01 等位基因携带者的高频率。
Intervirology. 2017;60(1-2):43-47. doi: 10.1159/000477810. Epub 2017 Aug 4.
引用本文的文献
1
Frequency of Human Leukocyte Antigen-B*57:01 Allele Carriers in People Living with HIV/AIDS in Türkiye.土耳其 HIV/AIDS 感染者中人类白细胞抗原-B*57:01 等位基因携带者的频率。
Curr HIV Res. 2024;22(4):266-269. doi: 10.2174/011570162X316158240801060941.
2
Human leukocyte antigen HLA-B*57:01 status in HIV-1 patients developing hypersensitivity reactions in Benin: a pilot study.在贝宁发生过敏反应的 HIV-1 患者中人类白细胞抗原 HLA-B*57:01 状态：一项初步研究。
BMC Res Notes. 2024 Jul 29;17(1):208. doi: 10.1186/s13104-024-06809-5.
3
Implementing Whole Genome Sequencing (WGS) in Clinical Practice: Advantages, Challenges, and Future Perspectives.在临床实践中实施全基因组测序（WGS）：优势、挑战和未来展望。
Cells. 2024 Mar 13;13(6):504. doi: 10.3390/cells13060504.
4
Are Community Pharmacists Ready to Deliver Pharmacogenomics Testing Services?社区药剂师是否准备好提供药物基因组学检测服务？
Pharmacy (Basel). 2023 Oct 26;11(6):170. doi: 10.3390/pharmacy11060170.
5
Distribution of Alleles and Haplotypes in Qatari: Recommendation for Establishing Pharmacogenomic Markers Screening for Drug Hypersensitivity.卡塔尔人群中基因等位基因和单倍型的分布：建立药物超敏反应药物基因组学标记物筛查的建议。
Front Pharmacol. 2022 Aug 8;13:891838. doi: 10.3389/fphar.2022.891838. eCollection 2022.
6
Risk Factors, Screening, Diagnosis, and Treatment of Osteoporosis in HIV-Infected Adults in an HIV Primary Care Clinic.HIV初级保健诊所中HIV感染成人骨质疏松症的危险因素、筛查、诊断及治疗
Can J Hosp Pharm. 2022 Jul 4;75(3):178-185. doi: 10.4212/cjhp.3144. eCollection 2022 Summer.
7
Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis.氯氮平诱导的粒细胞缺乏症的药物基因组学：系统评价和荟萃分析。
Pharmacogenomics J. 2022 Jul;22(4):230-240. doi: 10.1038/s41397-022-00281-9. Epub 2022 Jun 16.
8
Factors Influencing Immune Restoration in People Living with HIV/AIDS.影响艾滋病毒/艾滋病感染者免疫恢复的因素
J Clin Med. 2022 Mar 28;11(7):1887. doi: 10.3390/jcm11071887.
9
Advances in Liver Transplantation for Persons with Human Immunodeficiency Infection.人类免疫缺陷病毒感染者肝移植的进展
Curr Infect Dis Rep. 2022;24(3):39-50. doi: 10.1007/s11908-022-00776-3. Epub 2022 Mar 15.
10
Influence of HLA-B*5701 on 20 year survival rate among patients living with HIV.人类白细胞抗原 B*5701 对 HIV 感染者 20 年存活率的影响。
PLoS One. 2021 Aug 9;16(8):e0255834. doi: 10.1371/journal.pone.0255834. eCollection 2021.
本文引用的文献
1
An epidemiologic study to determine the prevalence of the HLA-B*5701 allele among HIV-positive patients in Europe.一项旨在确定欧洲 HIV 阳性患者中 HLA-B*5701 等位基因流行率的流行病学研究。
Pharmacogenet Genomics. 2010 May;20(5):307-14. doi: 10.1097/FPC.0b013e3283390666.
2
Successful implementation of a national HLA-B*5701 genetic testing service in Canada.在加拿大成功实施全国性HLA - B*5701基因检测服务。
Tissue Antigens. 2010 Jan;75(1):12-8. doi: 10.1111/j.1399-0039.2009.01383.x. Epub 2009 Oct 15.
3
Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-B*5701 in HIV-1-infected UK subjects.前瞻性流行病学研究人类白细胞抗原 (HLA)-B*5701 在英国 HIV-1 感染者中的流行率。
HIV Med. 2010 Mar;11(3):187-92. doi: 10.1111/j.1468-1293.2009.00762.x. Epub 2009 Sep 24.
4
Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America.美国传染病学会艾滋病医学协会《2009年更新：人类免疫缺陷病毒感染者管理的初级保健指南》
Clin Infect Dis. 2009 Sep 1;49(5):651-81. doi: 10.1086/605292.
5
The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.HLA-B*5701基因筛查指导HIV初始抗逆转录病毒治疗的成本效益
AIDS. 2008 Oct 1;22(15):2025-33. doi: 10.1097/QAD.0b013e3283103ce6.
6
First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America.北美首个利用HLA - B*5701筛查阿巴卡韦超敏反应的大型多中心开放标签研究。
AIDS. 2008 Aug 20;22(13):1673-5. doi: 10.1097/QAD.0b013e32830719aa.
7
High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.人类白细胞抗原B*5701作为白种人和黑种人免疫确诊阿巴卡韦超敏反应标志物的高敏感性。
Clin Infect Dis. 2008 Apr 1;46(7):1111-8. doi: 10.1086/529382.
8
Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility.阿巴卡韦超敏反应的药物遗传学：从药物基因组学假设到确证再到临床应用
Pharmacogenomics J. 2008 Dec;8(6):365-74. doi: 10.1038/tpj.2008.3. Epub 2008 Mar 11.
9
Abacavir hypersensitivity reaction: an update.阿巴卡韦超敏反应：最新进展。
Ann Pharmacother. 2008 Mar;42(3):387-96. doi: 10.1345/aph.1K522. Epub 2008 Feb 26.
10
HLA-B*5701 screening for hypersensitivity to abacavir.进行HLA-B*5701筛查以检测对阿巴卡韦的超敏反应。
N Engl J Med. 2008 Feb 7;358(6):568-79. doi: 10.1056/NEJMoa0706135.
Zotero 插件